1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy

BACKGROUND: To evaluate the efficacy and safety of half-dose photodynamic therapy (PDT combined with ranibizumab for polypoidal choroidal vasculopathy (PCV). PCV is commonly treated with a combination of anti-vascular endothelial growth factor and standard-dose photodynamic therapy (PDT). Choroidal...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Ian Y., Shi, Xuan, Gangwani, Rita, Zhao, Paul, Iu, Lawrence P., Li, Qing, Ng, Alex, Li, Xiaoxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485362/
https://www.ncbi.nlm.nih.gov/pubmed/26122636
http://dx.doi.org/10.1186/s12886-015-0061-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485362/
https://www.ncbi.nlm.nih.gov/pubmed/26122636
http://dx.doi.org/10.1186/s12886-015-0061-8

Ejemplares similares